Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Shpall, EJ, Clarke-Pearson, D, Soper, JT, Berchuck, A, Jones, RB, Bast, RC, Ross, M, Lidor, Y, Vanacek, K, and Tyler, T. "High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer." Gynecol Oncol 38, no. 3 (September 1990): 386-391.

Scholars@Duke

Olt, G, Berchuck, A, and Bast, RC. "The role of tumor markers in gynecologic oncology." Obstet Gynecol Surv 45, no. 9 (September 1990): 570-577. (Review)

Scholars@Duke

Soisson, AP, Geszler, G, Soper, JT, Berchuck, A, and Clarke-Pearson, DL. "A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy." Obstet Gynecol 76, no. 1 (July 1990): 106-109.

Scholars@Duke

Berchuck, A, Kamel, A, Whitaker, R, Kerns, B, Olt, G, Kinney, R, Soper, JT, Dodge, R, Clarke-Pearson, DL, and Marks, P. "Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer." Cancer Res 50, no. 13 (July 1, 1990): 4087-4091.

Scholars@Duke

Soisson, AP, Soper, JT, Clarke-Pearson, DL, Berchuck, A, Montana, G, and Creasman, WT. "Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer." Gynecol Oncol 37, no. 3 (June 1990): 390-395.

Scholars@Duke

Berchuck, A, Olt, GJ, Soisson, AP, Kamel, A, Soper, JT, Boyer, CM, Clarke-Pearson, DL, Leslie, DS, and Bast, RC. "Heterogeneity of antigen expression in advanced epithelial ovarian cancer." Am J Obstet Gynecol 162, no. 4 (April 1990): 883-888.

Scholars@Duke

Berchuck, A, Olt, GJ, Everitt, L, Soisson, AP, Bast, RC, and Boyer, CM. "The role of peptide growth factors in epithelial ovarian cancer." Obstet Gynecol 75, no. 2 (February 1990): 255-262.

Scholars@Duke

Berchuck, A, Rodriguez, G, Kamel, A, Soper, JT, Clarke-Pearson, DL, and Jr, RCB. "Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina." Obstetrics and Gynecology 76, no. 3 I (1990): 381-387.

Scholars@Duke

Olt, GJ, Berchuck, A, and Bast, RC. "Gynecologic tumor markers." Semin Surg Oncol 6, no. 6 (1990): 305-313. (Review)

Scholars@Duke

Soper, JT, Berchuck, A, Olt, GJ, Soisson, AP, Clarke-Pearson, DL, and Jr, RCB. "Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma." American Journal of Obstetrics and Gynecology 163, no. 4 PART 1 (1990): 1204-1209.

Full Text

Pages